Wikipedia

User:Mr. Ibrahem/Levomilnacipran

< User:Mr. Ibrahem
Mr. Ibrahem/Levomilnacipran
Clinical data
Trade namesFetzima
Other namesLevomilnacipran hydrochloride
AHFS/Drugs.comMonograph
Routes of
administration		By mouth (capsules)
Drug classSerotonin–norepinephrine reuptake inhibitor (SNRI)[1]
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability92%[2]
Protein binding22%[3]
MetabolismLiver (primarily by CYP3A4)[4]
Elimination half-life12 hours[4]
ExcretionKidney[4]
Identifiers
  • (1S,2R)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
Chemical and physical data
FormulaC15H22N2O
Molar mass246.354 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC=CC=C2
  • InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m0/s1 ☒N
  • Key:GJJFMKBJSRMPLA-DZGCQCFKSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Levomilnacipran, sold under the brand name Fetzima, is an antidepressant used to treat major depressive disorder.[1] While not approved for fibromyalgia, the similar medication milnacipran is.[1] It is taken by mouth.[1]

Common side effects include nausea, constipation, increased sweating, sexual dysfunction, and palpitations.[1] Other side effects may include suicide in those under 25 years, serotonin syndrome, high blood pressure, bleeding, mania, and urinary retention.[1] Safety in pregnancy is unclear.[5] It is a serotonin–norepinephrine reuptake inhibitor (SNRI) and an enantiomer of milnacipran.[1]

Levomilnacipran was approved for medical use in the United States in 2013 and Canada in 2015.[1][6] Approval was rejected in Australia in 2016 and has not been applied for in Europe.[6] In the United States it cost about 430 USD per month as of 2021.[7]

References edit

  1. ^ a b c d e f g h i j "Levomilnacipran Monograph for Professionals". Drugs.com. Archived from the original on 19 January 2021. Retrieved 21 November 2021.
  2. ^ "Fetzima (levomilnacipran) Extended-Release Capsules, for Oral Use. Full Prescribing Information". Forest Pharmaceuticals, Inc. Subsidiary of Forest Laboratories, Inc. St. Louis, MO 63045 USA. July 2014. Archived from the original on 17 August 2016. Retrieved 2 September 2016.
  3. ^ Alan F. Schatzberg; Charles B. Nemeroff (10 May 2017). The American Psychiatric Association Publishing Textbook of Psychopharmacology. American Psychiatric Pub. pp. 533–. ISBN 978-1-61537-122-8.
  4. ^ a b c Stephen M. Stahl (31 March 2017). Prescriber's Guide: Stahl's Essential Psychopharmacology. Cambridge University Press. pp. 373–376. ISBN 978-1-108-22874-9.
  5. ^ "Levomilnacipran (Fetzima) Use During Pregnancy". Drugs.com. Archived from the original on 1 December 2020. Retrieved 21 November 2021.
  6. ^ a b "Australian Public Assessment Report for Levomilnacipran (as hydrochloride)" (PDF). 2016. Archived (PDF) from the original on 21 November 2021. Retrieved 21 November 2021.
  7. ^ "Fetzima Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 21 November 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Levomilnacipran&oldid=1200750108"